A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: (Q84357255)
Jump to navigation
Jump to search
scientific article published on 11 June 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: |
scientific article published on 11 June 2012 |
Statements
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study (English)
A K L Reyners
L de Munck
F L G Erdkamp
W M Smit
K Hoekman
R I Lalisang
H de Graaf
A N M Wymenga
M Polee
H Hollema
M A T M van Vugt
P H B Willemse
DoCaCel Study Group